These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 26717245)

  • 1. Hiding in the Shadows: Philip Morris and the Use of Third Parties to Oppose Ingredient Disclosure Regulations.
    Velicer C; Glantz SA
    PLoS One; 2015; 10(12):e0142032. PubMed ID: 26717245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tobacco companies' efforts to undermine ingredient disclosure: the Massachusetts benchmark study.
    Velicer C; Aguinaga-Bialous S; Glantz S
    Tob Control; 2016 Sep; 25(5):575-83. PubMed ID: 26292701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ARTIST (Asian regional tobacco industry scientist team): Philip Morris' attempt to exert a scientific and regulatory agenda on Asia.
    Tong EK; Glantz SA
    Tob Control; 2004 Dec; 13 Suppl 2(Suppl 2):ii118-24. PubMed ID: 15564214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tobacco industry strategies to undermine the 8th World Conference on Tobacco or Health.
    Muggli ME; Hurt RD
    Tob Control; 2003 Jun; 12(2):195-202. PubMed ID: 12773731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Turning free speech into corporate speech: Philip Morris' efforts to influence U.S. and European journalists regarding the U.S. EPA report on secondhand smoke.
    Muggli ME; Hurt RD; Becker LB
    Prev Med; 2004 Sep; 39(3):568-80. PubMed ID: 15313097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cigarette company trade secrets are not secret: an analysis of reverse engineering reports in internal tobacco industry documents released as a result of litigation.
    Velicer C; Lempert LK; Glantz S
    Tob Control; 2015 Sep; 24(5):469-80. PubMed ID: 24920577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Making big tobacco give in: you lose, they win.
    Wander N; Malone RE
    Am J Public Health; 2006 Nov; 96(11):2048-54. PubMed ID: 17018823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tobacco industry's ITGA fights FCTC implementation in the Uruguay negotiations.
    Assunta M
    Tob Control; 2012 Nov; 21(6):563-8. PubMed ID: 22634569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "If we can just 'stall' new unfriendly legislations, the scoreboard is already in our favour": transnational tobacco companies and ingredients disclosure in Thailand.
    MacKenzie R; Collin J; Sriwongcharoen K; Muggli ME
    Tob Control; 2004 Dec; 13 Suppl 2(Suppl 2):ii79-87. PubMed ID: 15564225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How Philip Morris built Marlboro into a global brand for young adults: implications for international tobacco control.
    Hafez N; Ling PM
    Tob Control; 2005 Aug; 14(4):262-71. PubMed ID: 16046690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Application of Philip Morris' Litigation Prevention Program in South Korea.
    Kim JH; Kim J; Lee S
    Asia Pac J Public Health; 2021; 33(2-3):188-195. PubMed ID: 33383993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Courtesy and the challenges of implementing smoke-free policies in Japan.
    Bialous SA; Mochizuki-Kobayashi Y; Stillman F
    Nicotine Tob Res; 2006 Apr; 8(2):203-16. PubMed ID: 16766413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Fag Lady, revisited: Margaret Thatcher's efforts on behalf of the tobacco industry.
    Petticrew M; Krishnaratne S
    Public Health; 2014 Oct; 128(10):904-10. PubMed ID: 25239649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Philip Morris' FDA gambit: good for public health?
    Givel M
    J Public Health Policy; 2005 Dec; 26(4):450-68. PubMed ID: 16392744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. "Keep a low profile": pesticide residue, additives, and freon use in Australian tobacco manufacturing.
    Chapman S
    Tob Control; 2003 Dec; 12 Suppl 3(Suppl 3):iii45-53. PubMed ID: 14645948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding Philip Morris's pursuit of US government regulation of tobacco.
    McDaniel PA; Malone RE
    Tob Control; 2005 Jun; 14(3):193-200. PubMed ID: 15923470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. "A good personal scientific relationship": Philip Morris scientists and the Chulabhorn Research Institute, Bangkok.
    Mackenzie R; Collin J
    PLoS Med; 2008 Dec; 5(12):1737-48. PubMed ID: 19108600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Learning from Philip Morris: Japan Tobacco's strategies regarding evidence of tobacco health harms as revealed in internal documents from the American tobacco industry.
    Iida K; Proctor RN
    Lancet; 2004 May; 363(9423):1820-4. PubMed ID: 15172783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The tobacco industry and pesticide regulations: case studies from tobacco industry archives.
    McDaniel PA; Solomon G; Malone RE
    Environ Health Perspect; 2005 Dec; 113(12):1659-65. PubMed ID: 16330343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How Philip Morris unlocked the Japanese cigarette market: lessons for global tobacco control.
    Lambert A; Sargent JD; Glantz SA; Ling PM
    Tob Control; 2004 Dec; 13(4):379-87. PubMed ID: 15564622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.